ES2935729T3 - Métodos y composiciones para el tratamiento del cáncer - Google Patents

Métodos y composiciones para el tratamiento del cáncer

Info

Publication number
ES2935729T3
ES2935729T3 ES18856836T ES18856836T ES2935729T3 ES 2935729 T3 ES2935729 T3 ES 2935729T3 ES 18856836 T ES18856836 T ES 18856836T ES 18856836 T ES18856836 T ES 18856836T ES 2935729 T3 ES2935729 T3 ES 2935729T3
Authority
ES
Spain
Prior art keywords
ido1
inhibitor
cancer
agent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18856836T
Other languages
English (en)
Spanish (es)
Inventor
Alexander Muller
Arpita Mondal
Souvik Dey
George Prendergast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lankenau Institute for Medical Research
Original Assignee
Lankenau Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lankenau Institute for Medical Research filed Critical Lankenau Institute for Medical Research
Application granted granted Critical
Publication of ES2935729T3 publication Critical patent/ES2935729T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES18856836T 2017-09-14 2018-09-14 Métodos y composiciones para el tratamiento del cáncer Active ES2935729T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762558573P 2017-09-14 2017-09-14
PCT/US2018/051088 WO2019055786A1 (en) 2017-09-14 2018-09-14 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
ES2935729T3 true ES2935729T3 (es) 2023-03-09

Family

ID=65724068

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18856836T Active ES2935729T3 (es) 2017-09-14 2018-09-14 Métodos y composiciones para el tratamiento del cáncer

Country Status (5)

Country Link
US (2) US20200261414A1 (https=)
EP (2) EP4176876A1 (https=)
JP (2) JP2020534289A (https=)
ES (1) ES2935729T3 (https=)
WO (1) WO2019055786A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240084002A1 (en) * 2020-12-07 2024-03-14 Lankenau Institute For Medical Research Methods and compositions utilizing ido1-dependent vascularizing cells for the treatment of pathological conditions involving neovascularization
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
CN117651548B (zh) 2021-08-27 2026-03-03 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
CN119384281A (zh) 2022-04-15 2025-01-28 深圳艾欣达伟医药科技有限公司 使用th-302单药或联用parp抑制剂治疗癌症的方法
CN119233822A (zh) 2022-05-23 2024-12-31 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
KR20250160163A (ko) 2023-02-27 2025-11-11 아센타위츠 파마슈티컬즈 리미티드 용액, 동결건조 제형, 동결건조 제형 단위 패키지, 주사제, 및 주사제 제조 방법
WO2025026214A1 (zh) 2023-07-28 2025-02-06 深圳艾欣达伟医药科技有限公司 治疗p53基因突变或缺陷阴性癌症、肿瘤患者

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US7714139B2 (en) 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20080146624A1 (en) 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
WO2008036643A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008058178A1 (en) 2006-11-08 2008-05-15 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CA2706378C (en) 2007-11-20 2017-09-12 Lankenau Institute For Medical Research Disulfide chemotherapeutic agents and methods of use thereof
JP5465720B2 (ja) 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
NO2694640T3 (https=) 2011-04-15 2018-03-17
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
WO2016090174A1 (en) * 2014-12-03 2016-06-09 Auckland Uniservices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
EP4659747A2 (en) 2015-07-24 2025-12-10 Lumos Pharma, Inc. Salts and prodrugs of 1-methyl-d-tryptophan
EP3359150A4 (en) * 2015-10-05 2019-11-06 Calithera Biosciences, Inc. COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS
US20190241573A1 (en) * 2016-07-20 2019-08-08 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors

Also Published As

Publication number Publication date
WO2019055786A1 (en) 2019-03-21
US20240374566A1 (en) 2024-11-14
US20200261414A1 (en) 2020-08-20
EP4176876A1 (en) 2023-05-10
EP3681498B1 (en) 2022-10-05
EP3681498A4 (en) 2021-06-02
EP3681498A1 (en) 2020-07-22
JP2024023290A (ja) 2024-02-21
JP2020534289A (ja) 2020-11-26

Similar Documents

Publication Publication Date Title
ES2935729T3 (es) Métodos y composiciones para el tratamiento del cáncer
Strand et al. Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles
JP6730285B2 (ja) Ｒｎａ干渉組成物及び悪性腫瘍のための方法
ES2622527T3 (es) Inhibidores de CSF-1R para el tratamiento de tumores de cerebro
Carlsson et al. Emerging treatment strategies for glioblastoma multiforme
JP6949859B2 (ja) Ｄｂａｉｔ分子の全身投与によるガンの処置
Chou et al. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme
KR20240017986A (ko) 암 치료를 위한 조성물 및 방법
JP2020097598A (ja) メタドヘリン−ｓｎｄ１相互作用を遮断するペプチドの癌の治療としての使用
JP7382919B2 (ja) トランスフェリン受容体（ＴｆＲ）に対するＲＮＡアプタマー
Joseph et al. STING activation counters glioblastoma by vascular alteration and immune surveillance
US20190336520A1 (en) Use of a sirna for treating cancer
JP2017527615A (ja) 線維化疾患及び癌を治療するための組成物及び方法
Cina et al. A Novel Lipid Nanoparticle NBF-006 Encapsulating Glutathione S-Transferase P siRNA for the Treatment of KRAS-Driven Non–small Cell Lung Cancer
US20220054610A1 (en) Slow-cycling cell-rna based nanoparticle vaccine to treat cancer
US8740762B2 (en) Specific inhibition of cPLA2 enhances the efficacy of radiotherapy
de Oliveira Silva et al. New avenues for the treatment of immunotherapy-resistant pancreatic cancer
JP5762103B2 (ja) 頭頸部癌及び食道癌用抗癌剤及び増強剤
HK40093210A (en) Methods and compositions for the treatment of cancer
WO2019183482A1 (en) USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
KR20150083353A (ko) 경요도적 주입용 방광암 예방 또는 치료를 위한 약제학적 조성물
US20220125770A1 (en) Combination therapy of alk-positive neoplasia
JP7396577B2 (ja) Ａｒｌ４ｃを標的分子とするアンチセンスオリゴヌクレオチド、及び当該アンチセンスオリゴヌクレオチドを使用した核酸医薬
EP4532722A2 (en) Mirna-based cancer therapy with a tumor-navigating peptide
ES2843654T3 (es) Composiciones de interferencia por ARN y métodos para tumores malignos